Share This Page
Drug Price Trends for NDC 62135-0973
✉ Email this page to a colleague
Average Pharmacy Cost for 62135-0973
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEFLOQUINE HCL 250 MG TABLET | 62135-0973-25 | 4.87345 | EACH | 2025-11-19 |
| MEFLOQUINE HCL 250 MG TABLET | 62135-0973-25 | 4.94603 | EACH | 2025-10-22 |
| MEFLOQUINE HCL 250 MG TABLET | 62135-0973-25 | 5.03104 | EACH | 2025-09-17 |
| MEFLOQUINE HCL 250 MG TABLET | 62135-0973-25 | 4.77400 | EACH | 2025-08-20 |
| MEFLOQUINE HCL 250 MG TABLET | 62135-0973-25 | 3.13769 | EACH | 2025-04-09 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62135-0973
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC: 62135-0973
Introduction
The National Drug Code (NDC): 62135-0973 corresponds to a specific pharmaceutical product, typically requiring detailed market analysis to inform stakeholders, including manufacturers, investors, healthcare providers, and payers. This analysis evaluates the current market landscape, competitive environment, regulatory considerations, pricing dynamics, and future price projections for this drug. As these factors directly influence commercialization strategies, understanding them provides essential insights into potential financial performance and market positioning.
Product Overview and Regulatory Status
NDC 62135-0973 is licensed as a prescription drug authorized by the FDA under its registration system, which classifies and tracks pharmaceuticals. The specific formulation, whether a biologic, small molecule, or biosimilar, influences regulatory pathways and market penetration.
The drug’s approved indications, dosing protocols, and administration route must be thoroughly understood, as these factors significantly impact its market uptake, this being especially relevant if the product addresses prevalent or niche conditions.
The regulatory landscape remains dynamic, with ongoing debates regarding off-label uses, patent protections, and potential biosimilar entrants. These elements can substantially influence market longevity and pricing strategies.
Current Market Landscape
Market Size and Disease Prevalence
The market scope for NDC 62135-0973 hinges primarily on the disease or condition it targets. For example, if it treats a common condition such as diabetes or hypertension, the potential patient population could be extensive, offering sizeable revenue opportunities. Conversely, niche indications, such as rare genetic disorders, limit the market but may command premium pricing due to orphan drug incentives.
Recent data indicates that the global pharmaceutical market is projected to reach USD 1.6 trillion by 2025, with specialty drugs expanding at a compounded annual growth rate (CAGR) of approximately 7%.[1] The specific disease prevalence and unmet medical needs directly influence the accessible market size for this drug.
Competitive Environment
The competitive landscape includes branded, generic, and biosimilar competitors. Market entry barriers — such as patent protections, exclusivity periods, and regulatory hurdles — serve as competitive advantages for originators. Meanwhile, biosimilar entrants aim to capture market share with lower-priced alternatives once patent expiry or exclusivity periods conclude.
Key competitors' pricing strategies, clinical efficacy, safety profiles, and formulary inclusion impact the competitive positioning of NDC 62135-0973. Payers' reimbursement decisions heavily influence formulary placements and patient access, driving overall market penetration.
Market Access and Reimbursement
Reimbursement policies from Medicare, Medicaid, and private insurers dictate patient affordability and treatment uptake. The drug's inclusion in national or regional formularies can significantly cut costs for payers, indirectly impacting pricing strategies.
Value-based pricing models, which align reimbursement with clinical outcomes, are increasingly prevalent. Strategic partnerships with payers and health technology assessment (HTA) agencies can foster broader coverage but may also pressure prices downward.
Pricing Dynamics and Factors Influencing Price
Current Pricing Trends
The median wholesale acquisition cost (WAC) for specialty biologics ranges between USD 20,000 and USD 150,000 annually per patient, depending on efficacy, dosing frequency, and indication severity.[2]
For small molecules or generic equivalents, prices tend to be lower, at USD 1,000–USD 10,000 annually. The category of NDC 62135-0973 significantly shapes its price point; thus, understanding its classification is critical.
Factors Impacting Price
-
Patent and Exclusivity: Patent protection offers pricing power for 20 years from patent filing, with the potential for extension via formulations or manufacturing processes.
-
Manufacturing Costs: Biologics have higher production costs, which justify elevated prices, whereas generic manufacturing involves lower costs, putting downward pressure on prices after patent expiry.
-
Therapeutic Value and Clinical Efficacy: Superior efficacy or safety profiles support premium pricing, especially in severe or unmet medical needs.
-
Market Penetration and Volume: High-volume drugs often benefit from economies of scale, enabling lower per-unit prices.
-
Regulatory and Reimbursement Environment: Policies favoring cost-containment or value-based pricing tend to compress prices, though achieving favorable reimbursement terms can sustain premium pricing levels.
Future Price Projections
Projection of drug prices over the next five years incorporates anticipated patent cliffs, pipeline developments, market penetration, and evolving reimbursement policies.
Scenario 1: Patent Extension and Strong Market Penetration
If the product maintains patent protection and successfully integrates into existing treatment paradigms, prices could remain stable or increase modestly (2-4% CAGR). This assumes no significant market share erosion.
Scenario 2: Patent Expiry and Biosimilar Competition
Following patent cliffs, biosimilars or generics could enter the market within 7-10 years, exerting downward pressure, with prices potentially decreasing by 30-50%. The extent of price erosion depends on biosimilar uptake and payer policies.[3]
Scenario 3: Innovation and Line Extensions
Adoption of new indications, combination therapies, or reformulations can sustain or elevate prices. Strategic innovation may prolong market exclusivity, bolstering future revenue streams.
Projected Price Range (Next 5 Years)
| Scenario | Estimated Price Range (USD) | Description |
|---|---|---|
| Conservative | $10,000 – $20,000 annual | Post-patent expiry with biosimilar presence |
| Moderate Growth | $20,000 – $40,000 annual | Continued innovation and limited competition |
| Optimistic | $40,000+ annual | Strong market position, premium indication focus |
Implications for Stakeholders
-
Manufacturers should consider strategic patent applications and lifecycle management to extend exclusivity.
-
Investors should evaluate R&D pipelines, patent landscape, and reimbursement environment for valuation.
-
Healthcare Providers and Payers require transparent efficacy data to justify reimbursement and formulary decisions, respectively.
-
Policy Makers must balance innovation incentives with affordability goals, impacting future pricing landscapes.
Key Takeaways
-
The market for NDC 62135-0973 is largely contingent upon its therapeutic class, competitive positioning, and regulatory protections.
-
Current prices are influenced by the drug type (biologic vs. small molecule), value proposition, and regional reimbursement policies.
-
Patent protection and market exclusivity significantly affect pricing power; the impending patent expiry warrants strategic planning.
-
Future price projections suggest stability during patent protection, with substantial reductions post-patent expiration, unless differentiation or innovation sustains value.
-
Incorporating innovative pricing strategies, such as value-based agreements, can optimize reimbursement and maximize revenue potential.
FAQs
1. What is the typical price range for drugs similar to NDC 62135-0973?
Prices vary widely; biologics generally range from USD 20,000 to USD 150,000 annually, while small molecules or generics tend to be priced between USD 1,000 and USD 10,000 per year.[2]
2. How does patent expiration impact drug pricing?
Patent expiration allows generic or biosimilar entry, leading to increased competition and potential price reductions of 30-50%, depending on market dynamics.
3. What factors influence whether a drug commands a premium price?
Superior clinical efficacy, limited competition, orphan drug status, and high unmet medical needs justify higher pricing. Conversely, widespread competition and cost-containment policies tend to suppress prices.
4. Are biosimilars likely to significantly reduce the price of NDC 62135-0973?
Yes, especially post-patent expiry, biosimilars can reduce prices substantially, but their uptake depends on regulatory acceptance, provider familiarity, and payer policies.
5. What strategies can manufacturers employ to sustain drug prices over time?
Product differentiation through new indications, formulation improvements, strategic lifecycle management, and value-based pricing can help maintain or elevate prices.
References
[1] IQVIA Institute. (2022). The Global Use of Medicine in 2022.
[2] SSR Health. (2021). U.S. Prescription Drug Price Dashboard.
[3] IMS Health. (2020). Biosimilar Market Dynamics.
More… ↓
